Avigen's executives, though, resisted both BVF and a takeover offer from MediciNova, laying off the bulk of its staff, selling an early-stage program and stepping up efforts to get a partner for ...

MediciNova said today that it has finally worked out a deal to buy competing company Avigen for $37 million, or $1.24 per share. The deal represents a 7 percent discount tor Avigen's closing stock ...

Even so, by getting in with Avigen now, Bayer presumably gets a leg up on a future licensing deal, if and when the Alameda firm makes gene therapy possible for hemophilia A. Nov 20, 2000 Tom Abate ...

Proposal dependent on BVF nominees replacing current Avigen board and supports eventual takeover by MediciNova. Biotechnology Value Fund (BVF) intends to purchase Avigen for $1.00 per share, or ...

Friday, August 21, 2009 Medicinova Buys Avigen. San Diego-based MediciNova, a biotech firm developing small-molecule therapeutics, said Friday that it has reached an agreement with Alameda-based ...

MediciNova Inc. (NASDAQ:MNOV) will acquire Avigen Inc (NASDAQ:AVGN) for $1.24 per share in cash or secured convertible notes. While the stock is trading at a slight premium to the bid, we’re ...

Bayer Signs Deal With Avigen LEVERKUSEN, Germany (AP) — Bayer AG's American subsidiary signed a deal Friday with the U.S. biotechnology firm Avigen for worldwide rights to distribute ...

German pharmaceutical giant Bayer AG on Friday announced a $60 million collaboration with U.S. biotech firm Avigen Inc. on a gene-therapy treatment for hemophilia B, a rare inherited blood ...

CHICAGO (MarketWatch) -- Avigen Inc. said Tuesday that Chief Financial Officer Thomas Paulson will resign as of Jan. 31. Paulson said he looks forward to helping to "grow and develop other ...

NEW YORK (CBS.MW) -- Shares of Avigen fell 7.7 percent today after the company announced it will refocus its research and development drug efforts. In a statement released after the market's close ...

Avigen Inc., an Alameda, Calif., biotechnology company, said the U.S. Food and Drug Administration has approved a second clinical trial in humans of its gene-therapy treatment for hemophilia B ...